linjc16/ctgov huggingface dataset:
Assessing Peripheral Nerve Block Scoring Systems for Intra-Operative and Post-Operative Analgesia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Peripheral Nerve Block scoring systems are effective in predicting the achievement of intra-operative anaesthesia and post-operative analgesia.

Detailed Description
-----------------
Upper and lower extremity surgery is particularly suited to regional anaesthesia. Peripheral nerve blocks (PNB) can produce surgical anaesthesia in less than 30 minutes. PNBs have been associated with early outcome improvements when surgery is conducted awake or with light sedation. These benefits include reduced nausea and vomiting, improved patient satisfaction and accelerated recovery room and hospital discharge. PNBs can also provide effective postoperative pain relief. Currently there is no globally accepted standard by which to assess when surgical anaesthesia has been achieved following administration of PNBs. The decision as to when adequate surgical anaesthesia has been achieved and when surgery can then proceed is usually left to the discretion of the anaesthetist. The anaesthetist can assess nerve blockade though several motor and sensory function tests: cold, heat, touch and pinprick sensitivity. Several scoring systems have been described using these tests to estimate when surgical anaesthesia has been achieved but none have been independently validated outside of the original studies in which they have been described.

Official Title
-----------------
The Effectiveness of Peripheral Nerve Block Scoring Systems in Predicting the Success of a Block for Intra-Operative and Post-Operative Analgesia

Conditions
-----------------
Complication of Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists Grade I-IV Exclusion Criteria: Contraindications to regional anesthesia Language barrier Existence of neurologic disease affecting the operative site Severe psychiatric disease Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive value of block assessment score |  | 30 mins post block completion |
Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine the safety and efficacy of a dexamethasone iontophoretic transdermal patch for the treatment of pain associated with lateral epicondylitis (tennis elbow).

Detailed Description
-----------------
Detailed Description: This trial is a randomized, double-blind, placebo-controlled, parallel-group trial in subjects diagnosed with lateral epicondylitis (tennis elbow). Subjects entered into the trial will be assigned to one of four treatment groups. The total duration is up to 13 days of trial participation.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of a Dexamethasone Iontophoretic Transdermal Patch for the Treatment of Pain Associated With Lateral Epicondylitis

Conditions
-----------------
Lateral Epicondylitis, (Tennis Elbow)

Intervention / Treatment
-----------------
* Drug: Dexamethasone Iontophoretic Patch (low dose)
* Drug: Dexamethasone Iontophoretic Patch (high dose)
* Drug: Dexamethasone Passive Patch
* Drug: Placebo Patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with onset of lateral epicondylitis symptoms no more than 12 weeks prior to study entry Female patients of childbearing potential must agree to use a medically accepted form of birth control. Exclusion Criteria: Subjects with other medical conditions/injuries of the elbow that would account for pain in the area Subjects who would require continuation of current pain medications during treatment Must not have received a prior corticosteroid injection for lateral epicondylitis in the affected arm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Dexamethasone Iontophoretic Patch (low dose) | Drug: Dexamethasone Iontophoretic Patch (low dose)<br> <br> |
| Experimental: 2<br>Dexamethasone Iontophoretic Patch (high dose) | Drug: Dexamethasone Iontophoretic Patch (high dose)<br> <br> |
| Experimental: 3<br>Dexamethasone Passive Patch | Drug: Dexamethasone Passive Patch<br> <br> |
| Placebo Comparator: 4<br>Placebo Patch | Drug: Placebo Patch<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain severity assessed by VAS (Visual Analog Scale) |  | baseline to completion/termination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  | up to 13 days |
Patients With Non-ST-segment Elevation Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
There are two types of acute coronary syndrome (ACS): ACS with persistent ST segment elevation (ACS ST +) and ACS without ST segment elevation (non-ST + ACS). The incidence of non-ST + ACS is increasing and currently accounts for the majority of myocardial infarction (MI) hospitalizations, while that of ST + ACS is declining. Complications of MI, which include rhythm and conduction disturbances, are mainly associated with ACS ST +. It is recognized that these complications can occur during non-ST + ACS, but with less frequency. This frequency is not clearly established, and has been the subject of few studies. Recent studies in this direction suggest that the frequency of rhythmic complications is low during non-ST + ACS. However, the data collected concerns inter-hospital transport. The aim of the study is to estimate the frequency of occurrence of potentially fatal rhythmic complications in patients admitted to the emergency room and to the cardiology department for non-ST + ACS.

Official Title
-----------------
Frequency of Serious Rhythmic Complications in Patients With Non-ST-segment Elevation Acute Coronary Syndrome

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient (≥ 18 years old) Man or woman Patient admitted to the Emergency Department (SU) or to the Cardiology Department at the NHC between January 1, 2019 and December 31, 2020 Patient whose main diagnosis retained at the end of hospitalization is a non-ST + ACS Patient who did not express his opposition to the reuse of his data for scientific research purposes. Exclusion criteria: Subject having expressed opposition to participating in the study Subject under guardianship, curatorship or safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the frequency of occurrence of potentially fatal rhythmic complications in patients with non-ST segment elevation acute coronary syndrome |  | Files analysed retrospectively from January 01, 2019 to December 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Coronary Syndrome, ACS, ST segment elevation, Myocardial infarction
PMCF Study on the Safety of Linovera Emulsion for the Prevention of Cat-1 Pressure Ulcers, Vascular and DFU

Study Overview
=================
Brief Summary
-----------------
To assess the safety of Linovera® Emulsion in the prevention of Grade I Pressure ulcers, Vascular and Diabetic Foot Ulcers. To assess the performance of Linovera® Emulsion for the prevention of stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers.

Detailed Description
-----------------
Diverse parameters are to be used to assess the safety and efficacy of Linovera® Emulsion for the prevention of stage 1 pressure ulcer, vascular and diabetic foot ulcers. This study is designed to implement an action within the framework of a proactive Post Market Clinical Follow up (PMCF) activity as a part of our Post Market Surveillance (PMS).

Official Title
-----------------
Multicenter, Long-term, Single-arm and Observational PMCF Study on the Safety of Linovera Emulsion for the Prevention of Stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers (PRELINEM)

Conditions
-----------------
Pressure Ulcer

Intervention / Treatment
-----------------
* Device: Linovera emulsion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Signed informed consent Patients with the possibility to participate during up 6 month follow-up. At least one of these criteria: Patients with medium, high or very high risk of amputation due to a vascular or diabetic foot illness. Patients with medium, high or very high risk of developing a pressure ulcer due to any neuropathic foot pathology Patients with medium, high or very high risk of developing a pressure ulcer following Braden Scale. Exclusion Criteria: Age < 18 years Known allergies and/or hypersensitivity to any component of Linovera® Emulsion. Any medical or psychological disorder that, in the investigator's opinion, may interfere with the patient's ability to give informed consent and comply with the study procedures. Patients in the terminal stage or receiving chemotherapy. Patients with more than 3 active pressure ulcers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Linovera emulsion<br>No intervention. Routine clinical practice. | Device: Linovera emulsion<br>* Apply Linovera emulsion in clinical routine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events | Number of adverse events | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participant developing stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers | Number of participants developing stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers | 1 month |
Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation

Study Overview
=================
Brief Summary
-----------------
Dysphagia is a common reason for referal to the investigators Gastoenterology service. As many as 14% of patients undergoing radiological studies for dysphagia are found to have schatzki rings. Current recommendations for treatment of patients with symptomatic Schatzki rings are based on ancedotal experience and uncontrolled studies. The only randomized study on comparison of techniques the investigators were able to locate was published in 2000 and included only 26 patients. This study demonstrated that the biopsy techinque was as effective as and better tolerated than the standard dilation technique. Considering that the cost and time required for dilatation is greater than the basic biopsy technique, significant cost savings could be achieved using the biopsy technique. As well, patient satisfaction is an important factor considering that Schatzki rings can recur and repeated endoscopy is often required. Therefore, a study that shows a technique to be as or better than the current standard in effectiveness, cost, time, and patient comfort could lead to shift in current practice.

Detailed Description
-----------------
None available, study was withdrawn

Official Title
-----------------
Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation

Conditions
-----------------
Dysphagia, Schatzki Ring

Intervention / Treatment
-----------------
* Other: study withdrawn no details


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presenting to endoscopy unit with symptoms of dysphagia or known history of schatzki ring Exclusion Criteria: Prior esophageal or gastric surgery, severe esophagitis, coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Study withdrawn no details<br> | Other: study withdrawn no details<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography

Study Overview
=================
Brief Summary
-----------------
To test the ability of electron beam CT in evalting the coronary artery pattern in children with congenital heart disease.

Detailed Description
-----------------
To test the ability of electron beam CT in evalting the coronary artery pattern in children with congenital heart disease.

Official Title
-----------------
Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography

Conditions
-----------------
Heart Diseases

Intervention / Treatment
-----------------
* Procedure: CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - TOF, DORV, TGA, CCT Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: CT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accuracy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity |  |  | 
| specificity |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery
Evaluation of Omeprazole Effect on Glaucoma

Study Overview
=================
Brief Summary
-----------------
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Detailed Description
-----------------
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Official Title
-----------------
Evaluation of Omeprazole Effect on Glaucoma

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Drug: Omeprazole
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with glaucoma 18 to 70 years POAG patients, Pseudoexfoliation no history of other systemic disease no history of intraocular intervention no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication no present immune deficiency no addiction habit Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Omeprazole<br> | Drug: Omeprazole<br> <br> |
| Placebo Comparator: placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Study Overview
=================
Brief Summary
-----------------
Expanded access Protocol to treat LHON subjects with EPI743

Detailed Description
-----------------
Emergency use administration of EPI-743 to subjects with LHON. This Protocol was originally developed to treat a single subject but was expanded to treat several at a single institution.

Official Title
-----------------
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Conditions
-----------------
Leber's Hereditary Optic Neuropathy

Intervention / Treatment
-----------------
* Drug: EPI-743


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency treatment for subjects with LHON who are actively losing site in one eye Exclusion Criteria: Allergy to EPI-743 or sesame oil Clinical history of bleeding or abnormal PT/PTT Hepatic insufficiency with LFTs greater than 2-times normal Renal insufficiency requiring dialysis Fat malabsorption syndromes Any other concurrent inborn erros of metabolism Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis Anemia with a HCT <25

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock

Study Overview
=================
Brief Summary
-----------------
The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.

Official Title
-----------------
Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock

Conditions
-----------------
STEMI, Cardiogenic Shock, Acute Coronary Syndrome, microRNA

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years ST elevation by ECG diagnostic of STEMI Evidency of coronary occlusion in coronariography Signed informed consent Exclusion Criteria: Patients admitted from other hospitals Impossibility of getting blood samples in first 6h Declined consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiogenic Shock STEMI<br>Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock | |
| No Cardiogenic Shock STEMI<br>Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | up to 6 months |